Narcolepsy – Cannabis Research

Narcolepsy Research Dashboard

4

Primary Studies

1

Related Studies

5

Total Studies

Clinical Studies

0

Clinical Meta-analyses

0

Double-blind Clinical Trials

1

Clinical Trials

Pre-Clinical Studies

2

Meta-analyses/Reviews

1

Animal Studies

0

Laboratory Studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 5 studies associated with Narcolepsy.

Here is a small sampling of Narcolepsy studies by title:


Ready to become a subscriber? Go to our PRICING page. Want to learn more about Endocannabinoid Medicine? Buy a book.

Endocannabinoid Medicine 11 Keys to Deeper Healing paperback book published by CannaKeys

Endocannabinoid Medicine: 11 Keys to Deeper Healing

A clear, science-based guide to working with the endocannabinoid system for whole-body balance.

Buy Book
Cannabis for Chronic Pain Relief A dual Guide for Clinicians and Patients - a paperback book published by CannaKeys

Cannabis for Chronic Pain Relief: A Dual Guide for Patients and Clinicians

A practical, evidence-based guide to using cannabis and cannabinoids for chronic pain.

Buy Book

Narcolepsy Research Dashboard

4

Primary Studies

1

Related Studies

5

Total Studies

Clinical Studies

0

Clinical Meta-analyses

0

Double-blind Clinical Trials

1

Clinical Trials

Pre-Clinical Studies

2

Meta-analyses/Reviews

1

Animal Studies

0

Laboratory Studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 5 studies associated with Narcolepsy.

Here is a small sampling of Narcolepsy studies by title:


Ready to become a subscriber? Go to our PRICING page. Want to learn more about Endocannabinoid Medicine? Buy a book.

Endocannabinoid Medicine 11 Keys to Deeper Healing paperback book published by CannaKeys

Endocannabinoid Medicine: 11 Keys to Deeper Healing

A clear, science-based guide to working with the endocannabinoid system for whole-body balance.

Buy Book
Cannabis for Chronic Pain Relief A dual Guide for Clinicians and Patients - a paperback book published by CannaKeys

Cannabis for Chronic Pain Relief: A Dual Guide for Patients and Clinicians

A practical, evidence-based guide to using cannabis and cannabinoids for chronic pain.

Buy Book

Select New Condition

Filter Condition

Overview - Narcolepsy

Description of Narcolepsy

Narcolepsy is a neurological sleep-wake disorder where the brain has trouble regulating when you feel awake and when you feel sleepy. It’s not about being “tired all the time” in the usual sense — it’s more like the boundaries between sleep and wakefulness get thin, leaky, and unpredictable.


People with narcolepsy can feel perfectly alert one moment and suddenly overwhelmingly sleepy the next. These sleep attacks aren’t voluntary and often have nothing to do with how much rest someone got the night before. The brain simply loses its grip on wakefulness.


There are two main forms:


Narcolepsy Type 1: Often includes cataplexy, brief episodes where strong emotions (like laughter, surprise, or anger) trigger a sudden loss of muscle tone. You stay conscious, but your body temporarily “powers down.” It’s frightening the first time someone experiences it, though it’s painless and fleeting.


Narcolepsy Type 2: Similar daytime sleepiness, but without cataplexy.


People may also experience:



  • Fragmented nighttime sleep (oddly, they often wake up many times at night)

  • Sleep paralysis (waking up unable to move for a few seconds)

  • Hypnagogic or hypnopompic hallucinations (vivid dreamlike imagery right as they fall asleep or wake up)

  • Automatic behavior (continuing an activity while half-asleep and not remembering it)


The core issue is usually a loss of hypocretin (orexin), a neurotransmitter that keeps us awake and regulates REM sleep. In narcolepsy, REM can show up at the wrong time: during the day, during emotional moments, or seconds after falling asleep.


Even though the symptoms can be disruptive, narcolepsy is manageable, and people with it often lead full, active, creative lives with the right treatment, routines, and support.


Narcolepsy is often misunderstood because, unlike insomnia or most sleep disorders, its core problem isn’t about getting sleep; it’s about staying awake.


Here’s the brief discernment:



  • Narcolepsy is a neurological disorder where the brain loses its ability to regulate sleep–wake transitions. This causes sudden sleep attacks, overwhelming daytime sleepiness, episodes of muscle weakness (cataplexy), and sometimes dream-like hallucinations at sleep onset. The issue is intrusive REM sleep appearing at the wrong times.

  • Insomnia is a disorder of initiating or maintaining sleep. People want to sleep but can’t — due to hyperarousal, stress, circadian disruption, or medical conditions. Unlike narcolepsy, they don’t suddenly fall asleep during the day.


Other sleep disorders:



  • Sleep apnea: breathing disruptions repeatedly wake the person, causing poor sleep quality — the issue is obstructed airflow, not REM intrusion.

  • Restless legs syndrome: uncomfortable sensations create an urge to move the legs, interfering with falling asleep — a sensorimotor problem.

  • Circadian rhythm disorders: the internal clock is misaligned with the external world — e.g., delayed sleep phase disorder.

  • Parasomnias: unwanted behaviors during sleep (sleepwalking, night terrors), usually occurring during non-REM sleep and caused by arousal disorders, not REM misregulation.

Disease Classification

Condition: Narcolepsy
Disease Family:
Organ System: Nervous System
ICD-10 Chapter: Diseases of the nervous system
ICD-10 Code: G47.41

Narcolepsy Symptoms:

Excessive daytime sleepiness, sudden sleep attacks, cataplexy (sudden loss of muscle tone triggered by emotion), fragmented nighttime sleep, sleep paralysis, hypnagogic hallucinations (vivid dreams at sleep onset), hypnopompic hallucinations (vivid dreams upon awakening), automatic behaviors (continuing tasks while half-asleep), trouble concentrating, memory lapses, sudden REM onset during naps or sleep episodes.

Also known as:

Sleep disorder with sudden sleep attacks, chronic sleepiness disorder, extreme daytime sleepiness syndrome, sudden sleep onset disorder, sleep-attack syndrome, excessive daytime sleepiness syndrome (EDS), Gelineau’s disease, narcoleptic syndrome.

Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • Tetrahydrocannabinol (THC) can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol. 
  • THC is metabolized by an inhibitor of several enzymatic liver pathways referred to as cytochrome P450 (aka CYP450). There are more than 50 enzymes belonging to this enzyme family, several of which are responsible for the breakdown of common drugs such as antidepressants (e.g., amitriptyline, doxepin, fluvoxamine), antipsychotics (haloperidol, clozapine, Stelazine), beta-blockers (e.g., propranolol), bronchodilators (e.g., theophylline), or blood thinners (e.g., warfarin). Thus, patients taking these medication classes may find that THC increases the concentration and effects of these drugs and the impact duration.
  • Clinical observation (not yet confirmed by clinical trials) suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.

CBD Interaction with Pharmaceutical Drugs

  • Cannabidiol (CBD) may alter the action of metabolic enzymes (specific drug-transport mechanisms) and alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include anti-epileptics, psychiatric drugs, and drugs affecting metabolic enzymes.
  • Clinical observations (not yet confirmed by clinical trials) suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD.

If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.

THC/CBD Interaction with Pharmaceutical Drugs

In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.

If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.

Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).

However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg
  • THC low dose:  0.5 mg to 5 mg
  • THC medium dose:  6 mg to 20 mg
  • THC high dose:  21 mg to 50+ mg

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg
  • CBD medium dose: 20 mg to 99 mg
  • CBD high dose:  100 mg to 800+ mg (upper limits tested ~1,500mg)
Top

Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.